Adverse events appear to unblind clinical trials in irritable bowel syndrome
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Clinical trial design is challenging in irritable bowel syndrome (IBS) due in part to a high placebo effect. We postulated that the mere presence of an adverse event (AE) may unmask patients in clinical trials who are assigned to the active agent, and this may lead to higher reported efficacy. Methods: We evaluated therapies receiving at least a Grade 1B from the A merican C ollege of G astroenterology T ask F orce for IBS or which passed recent phase III clinical trials. Therapies with AE data derived from less than 50 patients in each study arm were excluded. Statistically significant excess AE were identified, risk difference was calculated for each AE, and incidence of AE in the treatment arm was reported. We examined the relationship of attributable drug benefit, defined as the reciprocal of number‐needed‐to‐treat found in literature, with various measures of AE incidence. Key Results: Attributable drug benefit correlated significantly with average AE risk difference, calculated as treatment arm AE incidence minus placebo arm AE incidence (R 2 = 0.70, p = 0.039), and also with highest treatment arm AE incidence (R 2 = 0.70, p = 0.038) for each therapy. There were also trends toward correlation with average treatment arm AE incidence (R 2 = 0.54, p = 0.096) and highest AE risk difference (R 2 = 0.63, p = 0.059) for each therapy. Conclusions & Inferences: Our study suggests that higher AE incidence on active therapy is associated with more beneficial patient‐reported outcomes in IBS clinical trials. This raises the issue of spontaneous unblinding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationPlacebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015591 · Cited by 900
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Savović, J., Jones, H., Altman, D., Harris, R., Jűni, P., Pildal, J., Als-Nielsen, B., Balk, E., Gluud, C., Gluud, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16350 · Cited by 668
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463
DROSSMAN, D. A., CHEY, W. D., JOHANSON, J. F., FASS, R., SCOTT, C., PANAS, R., & UENO, R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03881.x · Cited by 399
Ford, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261
Johnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
Cited by
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“tors, but not for individual patients (Shah et al., 2014), something that clearly calls for improved blinding methods, e.”
BackgroundPlacebo effect in the treatment of depression and anxiety
Kirsch, I. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00407 · Cited by 205
Placebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Placebo effects in psychotherapy: a framework
Enck, P., & Zipfel, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00456 · Cited by 115
Shah, E. D., Suresh, S., Jou, J., Chey, W. D., & Stidham, R. W. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000530 · Cited by 23
Self-citation
Metadata
- Authors
- Shah, E., Triantafyllou, K., Hana, A. A., & Pimentel, M.
- Venue
- Neurogastroenterology & Motility
- Publisher
- Wiley
- Published
- 2013-12-18
- Volume
- 26
- Issue
- 4
- Pages
- 482-488
- ISSN
- 1350-1925 (ISSN-L)
- 1365-2982
- OpenAlex
- W1987161384
- Cited by
- 23
- References
- 11
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse events appear to unblind clinical trials in irritable bowel syndrome. https://app.cochat.ai/papers/10.1111/nmo.12289
- The paper
- Shah, E., Triantafyllou, K., Hana, A. A., & Pimentel, M. (2014). Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.12289
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.